Opportunistic Infections Are Uncommon with Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

被引：0
|
作者：
Al-Ameri, Ali [1 ]
Kantarjian, Hagop [1 ]
Borthakur, Gautam [1 ]
Bahceci, Erkut [2 ]
Szatrowski, Ted [3 ]
Damokosh, Andrew [4 ]
Cortes, Jorge [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Bristol Myers Squibb Co, Plainsboro, NJ USA
[3] Bristol Myers Squibb Co, Princeton, NJ USA
[4] Bristol Myers Squibb Co, Wallingford, CT USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：459 / 459
页数：1
相关论文
共 50 条
  • [1] Molecular Responses to Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Michor, Franziska
    Olshen, Adam
    Gonen, Mithat
    Jones, Dan
    Rios, Mary Beth
    O'Brien, Susan
    Cortes, Jorge
    BLOOD, 2008, 112 (11) : 1114 - 1115
  • [2] Therapy of Early Chronic Phase Chronic Myeloid Leukemia (CML-CP) with Lower Dose Dasatinib
    Naqvi, Kiran
    Cortes, Jorge
    Skinner, Jeffrey
    Jabbour, Elias
    Pemmaraju, Naveen
    Borthakur, Gautam
    Estrov, Zeev
    Bose, Prithviraj
    Thompson, Philip
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S15 - S16
  • [3] Resistance, Outcome and the Development of Mutations with Dasatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).
    Shah, Neil
    Bahceci, Erkut
    Lambert, Alexandre
    Ploughman, Lynn
    Radich, Jerald
    BLOOD, 2009, 114 (22) : 460 - 460
  • [4] Phase II trial of dasatinib (DAS) in pediatric patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP).
    Gore, Lia
    Kearns, Pamela
    Lee, Maria Lucia
    De Souza, Carmino Antonio
    Bertrand, Yves
    Hijiya, Nobuko
    Stork, Linda C.
    Chung, Nack-Gyun
    Cardenas-Cardos, Rocio
    Saikia, Tapan
    Fagioli, Franca
    Seo, Jong-Jin
    Landman-Parker, Judith
    Lancaster, Donna
    Place, Andrew E.
    Rabin, Karen R.
    Sacchi, Mariana
    Swanink, Rene
    Zwaan, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] DASATINIB IN CHILDREN AND ADOLESCENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FROM A PHASE 2 TRIAL
    Zwaan, C. M.
    Kearns, P.
    Lee, M. L. D. M.
    De Souza, C. A.
    Bertrand, Y.
    Hijiya, N.
    Stork, L.
    Chung, N-G
    Cardos, R. Cardenas
    Saikia, T.
    Fagioli, F.
    Seo, J. J.
    Landman-Parker, J.
    Lancaster, D.
    Place, A. E.
    Rabin, K. R.
    Sacchi, M.
    Swanink, R.
    Gore, L.
    HAEMATOLOGICA, 2017, 102 : 150 - 151
  • [6] Use of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP)
    Atallah, E. L.
    Kantarjian, H.
    O'Brien, S.
    Jones, D.
    Borthakur, G.
    Nicaise, C.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Dasatinib (SPRYCEL®) in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP).
    Cortes, Jorge
    O'Brien, S.
    Jones, D.
    Borthakur, G.
    Giles, F.
    Nicaise, C.
    Kantarjian, H. M.
    BLOOD, 2006, 108 (11) : 613A - 613A
  • [8] Ponatinib As Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Jain, Preetesh
    Kantarjian, Hagop M.
    Jabbour, Elias
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Gachimova, Evguenia
    Ferrajoli, Alessandra
    Kornblau, Steven M.
    Ravandi, Farhad
    O'Brien, Susan
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
  • [9] Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
    Cortes, Jorge E.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Quintas-Cardama, Alfonso
    Ravandi, Farhad
    Gachimova, Evguenia
    Estrov, Zeev
    Jabbour, Elias
    O'Brien, Susan
    Kantarjian, Hagop
    BLOOD, 2013, 122 (21)
  • [10] EFFICACY OF DASATINIB IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED CHRONIC MYELOGENOUS LEUKEMIA (CML) IN EARLY CHRONIC PHASE (CML-CP)
    Cortes, J.
    Borthakur, G.
    Jones, D. M.
    O'Brien, S.
    Koller, C. A.
    Nicaise, C.
    Garcia-Manero, G.
    Ferrajoli, A.
    Kantarjian, H. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 349 - 349
12345